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Aims Much controversy exists concerning the efﬁcacy of primary prophylactic implantable cardioverter-deﬁbrillators
(ICDs) in patients with low ejection fraction due to coronary artery disease (CAD) or dilated cardiomyopathy
(DCM). This is also related to the bias created by function improving interventions added to ICD therapy, e.g. resyn-
chronization therapy. The aim was to investigate the efﬁcacy of ICD-only therapy in primary prevention in patients
with CAD or DCM.
Methods
and results
Public domain databases, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials, were searched
from 1980 to 2009 for randomized clinical trials of ICD vs. conventional therapy. Two investigators independently
abstracted the data. Pooled estimates were calculated using both ﬁxed-effects and random-effects models. Eight
trials were included in the ﬁnal analysis (5343 patients). Implantable cardioverter-deﬁbrillators signiﬁcantly
reduced the arrhythmic mortality [relative risk (RR): 0.40; 95% conﬁdence interval (CI): 0.27–0.67] and all-cause
mortality (RR: 0.73; 95% CI: 0.64–0.82). Regardless of aetiology of heart disease, ICD beneﬁt was similar for
CAD (RR: 0.67; 95% CI: 0.51–0.88) vs. DCM (RR: 0.74; 95% CI: 0.59–0.93).
Conclusions The results of this meta-analysis provide strong evidence for the beneﬁcial effect of ICD-only therapy on the survival
of patients with ischaemic or non-ischaemic heart disease, with a left ventricular ejection fraction ≤35%, if they are 40
days from myocardial infarction and ≥3 months from a coronary revascularization procedure.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Sudden cardiac and arrhythmic death (SCD) account for approxi-
mately 50% of the mortality in patients with left ventricular dys-
function.
1 Life-threatening ventricular arrhythmias are involved in
the majority of SCD occurrences.
2 Randomized clinical trials
have shown that the implantable cardioverter-deﬁbrillator (ICD)
is the most effective therapy currently available to prevent SCD
by terminating ventricular arrhythmias.
3–6 Therefore, the ICD
has become the standard therapy for primary and secondary pre-
vention of SCD in patients with left ventricular dysfunction.
7,8 The
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therapy created not only possibilities to improve cardiac function
in subgroups, but also inﬂuenced the outcome with respect to
morbidity and mortality.
9,10 In contrast, concerns were raised on
the magnitude of the effectiveness of ICD therapy certainly in
this era when the majority of infarction patients receive primary
coronary intervention in a reasonable time frame.
11 Some compli-
cations became more evident in the past few years, and
co-morbidity became considered as limitation as it is associated
with a less favourable outcome.
12,13 Given these recent concerns
about ICD therapy, we performed a systematic review and
meta-analysis of randomized trials of primary prevention of SCD
in patients with heart failure due to coronary artery disease
(CAD) or dilated cardiomyopathy (DCM), which constitute the
largest two subgroups of potential ICD recipients. We examined
the efﬁcacy of ICD-only therapy without CRT on rates of all-cause
mortality and arrhythmic mortality. In addition, we assessed the
rates of delivered ICD therapies.
Methods
Search strategy
A comprehensive search of public domain databases was performed to
identify randomized clinical trials comparing ICD therapy with conven-
tional medical therapy in patients with left ventricular dysfunction. The
public domain databases MEDLINE (January 1980 to January 2009),
EMBASE (1991 to the last quarter of 2008), and the Cochrane
Central Register of Controlled Trials (last quarter of 2008) were
searched using the terms implantable cardioverter-deﬁbrillator, implanta-
ble deﬁbrillator, randomized controlled trials, clinical trials, mortality,
sudden death, and prevention. The search was restricted to humans
and English language literature. In addition, we performed a manual
search of secondary sources including references of initially identiﬁed
articles and a search of reviews, editorials, commentaries, and pro-
ceedings from international cardiology meetings.
Eligibility and data abstraction
Studies considered for inclusion met the following criteria: the design
was a randomized controlled clinical trial; patients were randomly
assigned to ICD-only therapy excluding CRT vs. conventional
medical therapy; the study population consisted of patients with left
ventricular dysfunction deemed to be at high risk for sudden cardiac
death or developing ventricular arrhythmias; and the main endpoints
included all-cause mortality, cardiac mortality, or arrhythmic mortality.
Trials in patients who survived sudden cardiac death or unstable ven-
tricular arrhythmias (secondary prevention) were excluded. We also
excluded trials in patients with inherited arrhythmic disorders, trials
that did not report any of the main endpoints of interest, or trials
with crossover rates greater than 50% between study groups.
The selection of studies, quality assessment, and data abstraction
were performed independently by two investigators (D.A.M.J.T. and
L.J.). The criteria for quality assessment included study design aspects
as randomized clinical trial, description of crossover, withdrawals and
dropouts, completeness of follow-up, and objectivity of the outcome
assessment.
14 Data regarding detailed inclusion criteria as patient
characteristics [number, mean age, gender, left ventricular ejection
fraction (LVEF)], ICD device type, duration of follow-up, rates of cross-
over, all-cause mortality, cardiac mortality, and arrhythmic mortality
(as available) were abstracted from each study. Studies were
grouped according to the aetiology of cardiomyopathy.
Data analysis
A meta-analysis of summary statistics from the individual trials was per-
formed. For each study, data regarding all-cause mortality were used to
calculate the risk ratios (RRs) and 95% conﬁdence intervals (CIs). The
RRs from each included trial were pooled using both ﬁxed- and
random-effects models that used weighting based on the inverse of
the variance calculated according to DerSimonian and Laird.
15 Evi-
dence of statistical heterogeneity among the trial-speciﬁc RRs was
checked and quantiﬁed by the I
2 statistic, and a P-value ≤0.05 was con-
sidered statistically signiﬁcant. When no signiﬁcant statistical hetero-
geneity was identiﬁed, the ﬁxed effect was preferentially used as the
summary measure. In case of statistical heterogeneity, sensitivity analy-
sis was performed to assess the contribution of each study to the
pooled estimate by excluding individual studies one at a time and
the pooled estimate was recalculated for the remaining studies.
When pooled analysis still resulted in a signiﬁcant heterogeneity, the
random-effects model was used. Data analysis was performed with




The selection of the included randomized clinical trials is shown in
Figure 1. The search retrieved 435 potential relevant manuscripts.
A total of 372 were excluded after the examination of the title
and abstract. Of the 63 articles retrieved for further examination,
8 randomized clinical trials of ICD therapy for primary prevention
were included for the analysis. No evidence of publication bias was
found by funnel-plot analysis.
Qualitative ﬁndings
The included trials were randomized and controlled. The analysed
primary prevention trials were the Multicenter Automatic Deﬁbrilla-
tor Implantation Trial (MADIT),
3 the Coronary Artery Bypass Graft
Patch trial (CABG Patch),
16 the Cardiomyopathy Trial (CAT),
17
Figure 1 Selection of trials included in the meta-analysis.
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5 the Amiodarone vs. Implantable Cardioverter-
Deﬁbrillator Randomized Trial (AMIOVIRT),
18 the Deﬁbrillator in
Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)
trial,
19 the Deﬁbrillators in Acute Myocardial Infarction Trial
(DINAMIT),
20 and the Sudden Cardiac Death in Heart Failure
Trial (SCD-HeFT).
6 The Multicenter Unsustained Tachycardia Trial
(MUSTT) and the Comparison of Medical Therapy, Pacing and Deﬁ-
brillators in Chronic Heart Failure (COMPANION) trial were
excluded from the analysis.
21,22 The MUSTT trial was not a random-
ized controlled trial of ICD therapy, but compared with electro-
physiological study guided antiarrhythmic therapy, including Class Ic
drugs, in this way selecting patients for ICD therapy with empirical
therapy. It is well known that Ic drugs are proarrhythmic.
23,24 The
COMPANIONtrialwasnotacomparisonbetweenICDandconven-
tional therapy, but studied the effects of CRT in a subgroup with
pacing and a subgroup with ICDs, and therefore is not reporting on
the effect of ICD-only therapy.
The characteristics of the included trials are presented in
Table 1. In the eight trials, 5343 patients were randomly assigned
to ICD therapy or conventional therapy. Of these trials, four
trials evaluated patients with ischaemic heart disease (MADIT,
CABG Patch, MADIT II, and DINAMIT), three trials examined
patients with non-ischaemic heart disease (CAT, AMIOVIRT, and
DEFINITE), and one trial (SCD-HeFT) enrolled patients with
CAD and DCM.
The baseline clinical characteristics of patients are presented in
Table 2. The mean age of the trial participants was 60 years, 79%
were male, and CAD was present in 73%. The mean LVEF was
25% (range 21–28%), 59% of patients had New York Heart





The MADIT, MADIT II, and SCD-HeFT trials showed signiﬁcant
reductions in all-cause mortality with relative risk (RR) reductions
ranging from 22 to 59%. In CABG Patch and DINAMIT, no
reductions in all-cause mortality were found (RR: 1.07; 95% CI:
0.81–1.42, and RR: 1.08; 95% CI: 0.76–1.55, respectively). All
these trials, except DINAMIT, mandated that patients should be
enrolled if they were at least 3 weeks after myocardial infarction.
Deﬁbrillators in Acute Myocardial Infarction Trial was the only
study designed to test ICD therapy as primary prevention in
patients recovering from an acute myocardial infarction. The
MADIT, MADIT II, and SCD-HeFT trials excluded patients who
underwent coronary revascularization within 1 month before
enrolment, whereas in CABG Patch, patients were enroled at
the time of coronary artery bypass surgery.
When the results of the ﬁve randomized trials were pooled, we
found statistical evidence of heterogeneity (I
2 ¼ 74.9%; P ¼ 0.003).
To assess the impact of heterogeneity on the pooled effect esti-
mate, we performed sensitivity analysis (Table 3). After exclusion
of CABG Patch and DINAMIT, no statistical evidence of hetero-
geneity was present (I
2 ¼ 61.5%; P ¼ 0.07). Pooled analysis using
a ﬁxed-effects model of the remaining studies showed a 29% RR
...............................................................................................................................................................................
Table 1 Characteristics of included studies







MADIT, 1996 EF ≤0.35; MI ≥3 weeks before entry; NSVT;
NYHA I–III
196 95 27 ICD therapy resulted in 54% RR
reduction, P ¼ 0.009
CABG Patch,
1997
EF ≤0.35; abnormal SAECG, scheduled for
CABG; NYHA I–III
900 446 32 ICD therapy did not reduce mortality,
P ¼ 0.64
CAT, 2002 EF ≤0.30; new onset DCM; NYHA II–III 104 50 66 ICD therapy did not reduce mortality,
P ¼ 0.55
MADIT II, 2002 EF ≤0.30; MI ≥1 month before entry; NYHA
I–III
1232 742 20 ICD therapy resulted in 31% RR
reduction, P ¼ 0.016
AMIOVIRT,
2003
EF ≤0.35; DCM; asymptomatic NSVT; NYHA
I–III
103 51 36 ICD therapy did not reduce mortality,
P ¼ 0.80
DEFINITE, 2004 EF ≤0.35; DCM; NSVT, NYHA I–III 458 229 29 ICD therapy resulted in 35% RR
reduction, P ¼ 0.08
DINAMIT, 2004 EF ≤0.35; within 6–40 days of MI; NYHA
I–III; abnormal HRV




EF ≤0.35; 3 months optimal medical therapy;
NYHA II–III
2521 829 45.5
a ICD therapy resulted in 23% RR
reduction, P ¼ 0.007
AMIOVIRT, Amiodarone vs. Implantable Deﬁbrillator Randomized Trial; CABG Patch, Coronary Artery Bypass Graft Patch trial; CAT, Cardiomyopathy Trial; DCM, dilated
cardiomyopathy; DEFINITE, Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Deﬁbrillator in Acute Myocardial Infarction Trial; EF, left
ventricular ejection fraction; HRV, heart rate variability; MADIT, Multicenter Automatic Deﬁbrillator Implantation Trial; MI, myocardial infarction; NYHA, New York Heart
Association; NSVT, non-sustained ventricular tachycardia; SAECG, signal-averaged ECG; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
aMedian
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39%; P , 0.0001). Analysis with a random-effects model yielded
a 33% RR reduction in all-cause mortality (95% CI: 12–49%; P ¼
0.004).
Dilated cardiomyopathy
A tendency towards a reduction in all-cause mortality by ICD
therapy was found in two trials (DEFINITE and SCD-HeFT). The
DEFINITE trial showed a RR of 0.65 for all-cause mortality with
ICD therapy (95% CI: 0.40–1.06; P ¼ 0.08). The RR for all-cause
mortality was 0.74 in the SCD-HeFT trial (95% CI: 0.55–1.00).
The CAT and AMIOVIRT trials found no reduction in all-cause
mortality with ICD therapy compared with conventional therapy.
When we pooled the data, the RR for all-cause mortality was
0.74 (95% CI: 0.59–0.93; P ¼ 0.009) both in random- and
ﬁxed-effects models. No statistical evidence for heterogeneity
was present among the trials enroling patients with DCM (I
2 ¼
0%; P ¼ 0.98).
Combined analysis
When we pooled the data of CAD and DCM, the summary of RR
for all-cause mortality was 0.72 (95% CI: 0.64–0.82; P , 0.0001)
with ICD therapy (Figure 2). No statistical evidence of heterogen-
eity was found (I
2 ¼ 0%; P ¼ 0.49). The pooled analysis using a
ﬁxed-effects model demonstrates that ICD therapy signiﬁcantly
reduces the all-cause mortality, both in patients with CAD (RR:
0.71; 95% CI: 0.61–0.83) and DCM (RR: 0.74; 95% CI: 0.59–
0.93). No signiﬁcant differences in ICD beneﬁt were found





Among the 2774 patients randomized to ICD therapy, there
were 98 sudden cardiac deaths compared with 227 sudden
cardiac deaths among the 2569 patients randomized to conven-
tional therapy. A pooled analysis using a ﬁxed-effects model
demonstrated a 60% relative reduction in arrhythmic mortality
(RR: 0.40; 95% CI: 0.31–0.50; P , 0.0001) with ICD therapy
(Figure 3). No statistical heterogeneity was found among the
trials (I
2 ¼ 0%; P ¼ 0.84). Subanalysis of SCD-HeFT demon-
strated a signiﬁcant reduction of arrhythmic mortality in CAD
(RR: 0.43; 95% CI: 0.27–0.67) and DCM (RR: 0.34; 95% CI:
0.17–0.70).
Implantable cardioverter-deﬁbrillator therapy during follow-up
The appropriateness of ICD therapy could not be assessed reliably
in the MADIT and in the CABG Patch trial, since only a small
number of devices had the capacity of electrogram storage. The
remaining six trials presented data on the number of patients
............. ....................................................................
...............................................................................................................................................................................
Table 2 Baseline clinical characteristics of patients assigned to implantable cardioverter-deﬁbrillator therapy
Study Age (years) Men (%) EF (%) NYHA
(%)
CAD (%) Pharmcological therapy (%)
II III Amiodarone b-blocker Digoxin ACE/ARB
MADIT 62+99 2 2 7 +7 II or III, 63 100 2 26 58 60
CABG Patch 64+98 7 2 7 +6 II or III, 71 100 4 18 69 55
CAT 52+12 86 24+6 67 33 0 NA 4 86 94
MADIT II 64+10 84 23+5 35 25 100 13 70 72 68
AMIOVIRT 58+11 67 22+10 64 16 0 NA 52 71 85
DEFINITE 58 73 21 54 21 0 4 86 42 97
DINAMIT 62+11 76 28+5 NA NA 100 8 87 NA 95
SCD-HeFT 60
a 76 25
a 71 29 52 NA 69 67 94
ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blocker; AMIOVIRT, Amiodarone vs. Implantable Deﬁbrillator Randomized Trial; CABG Patch, Coronary Artery
Bypass Graft Patch trial; CAT, Cardiomyopathy Trial; DEFINITE, Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Deﬁbrillator in Acute
Myocardial Infarction Trial; EF, left ventricular ejection fraction; MADIT, Multicenter Automatic Deﬁbrillator Implantation Trial; MI, myocardial infarction; NYHA, New York Heart
Association; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
aMedian.
................................................................................
Table 3 Sensitivity analysis of randomized primary









MADIT 0.87 0.77–0.99 0.04 0.03
CABG
Patch
0.77 0.68–0.88 0.01 0.0002
MADIT II 0.88 0.77–1.00 0.003 0.05
DINAMIT 0.80 0.70–0.91 0.005 0.0005
SCD-HeFT 0.86 0.74–1.00 0.002 0.05
Removal of each trial (shown in column 1) followed by re-analysis of the pooled
relative risk (RR; column 2) and 95% conﬁdence intervals (95% CIs; column 3) for
the remaining trials. P-values for heterogeneity and ICD beneﬁt are shown in
columns 4 and 5.
Meta-analysis of prophylactic ICD therapy 1567who experienced appropriate ICD therapy delivered for ventricu-
lar tachyarrhythmias (Figure 4). The mean proportion of patients
with appropriate ICD therapy was 22.9% (range 17.8–31.4%).
The delivery of inappropriate ICD therapy was observed in
16.5% of the patients.
Discussion
Arrhythmic death and implantable
cardioverter-deﬁbrillator interventions
Previous meta-analyses demonstrated that the ICD is associated
with a 50% RR reduction for arrhythmic death in secondary pre-
vention patients.
25,26 In primary prevention, the risk reduction
for arrhythmic death is similar. In SCD-HeFT, as was conﬁrmed
in this analysis, the beneﬁt of ICD therapy in reducing arrhythmic
death is similar, regardless of whether a patient had left ventricular
dysfunction caused by CAD or DCM.
27 The proportion of ICD
interventions in the follow-up cannot be used as a surrogate for
its efﬁcacy in preventing mortality, but shows that ICDs are effec-






28 Former meta-analysis did not exclude
DINAMIT and CABG Patch, which both contributed signiﬁcantly
in the heterogeneity of the pooled analysis in CAD. This resulted
in a homogeneous CAD population in our observation. The
observed beneﬁt for the entire group and for DCM remains
present in spite of the inclusion of small negative trials studying
DCM, and additional exclusion of trials such as MUSTT, comparing
ICD therapy with potentially proarhythmic drug therapy as
control.
23,24 Further, in contrast to previous meta-analyses,
26,28–30
we excluded trials with a potential beneﬁt of CRT (as COMPA-
NION), as CRT alone already has a beneﬁt on survival.
9,10 This is
part of the explanation that ICD therapy in non-ischaemic cardio-
myopathy only received a recommended Class I-B indication in the
2006 and 2008 international guidelines.
7,8 The beneﬁt of CRT is
most evident in patients with DCM and left bundle branch block,
31
but its impact on mortality in comparison with ICD was not
evident in a recent study in patients with mild heart failure,
32 con-
ﬁrming our position that the beneﬁt of both intervention
modalities (ICD and CRT) should be further clariﬁed.
Implantable cardioverter-deﬁbrillator-
only beneﬁt
A huge variation exists in the utilization of ICDs with or without
CRT in different social and medical environments.
33 Uncertainty
Figure 2 All-cause mortality among patients with ischaemic or non-ischaemic heart disease randomized to implantable cardioverter-
deﬁbrillator (ICD) vs. conventional therapy in primary prevention. For each randomized trial, the number of deaths (Events) and the
number assigned (Total) are shown. The point estimates of the relative risk (RR) for individual studies are represented by squares with
95% conﬁdence intervals (CIs) shown as bars. The midpoint of the diamond represents the overall pooled estimate of the RR, and the 95%
CI is represented by the horizontal tips of the diamond. AMIOVIRT, Amiodarone vs. Implantable Deﬁbrillator Randomized Trial; CAT, Cardi-
omyopathy Trial; DEFINITE, Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; MADIT, Multicenter Automatic Deﬁbrilla-
tor Implantation Trial; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
D.A.M.J. Theuns et al. 1568of the effect of the ICD alone in the present era of infarction
therapy, and doubts on the value of ICDs for DCM, e.g. in the
Dutch guidelines,
34 prompted us to perform this meta-analysis,
which was performed for the ﬁrst time with unpublished data on
SCD-HeFT (separate mortality data for ischaemic and non-
ischaemic cardiomyopathy).
The timing of device implantation after myocardial infarction
remains debated. The role of ICD therapy in the early post-
myocardial infarction period was examined by the DINAMIT
study.
20 No beneﬁt of ICD therapy in reducing all-cause mortality
was observed when device implantation occurred within 40 days
post-acute myocardial infarction. A recent study, Immediate Risk
Stratiﬁcation Improves Survival (IRIS), that included patients very
early after infarction with additional risk factors conﬁrmed this
ﬁnding.
35 Time-dependent beneﬁt of ICD therapy was observed
in the MADIT II study.
36 Beneﬁt was present for remote events
more than 18 months after myocardial infarction, as could be
expected from other observations.
2
Thus, this analysis conﬁrms that ICD-only therapy reduces the
RR for all-cause mortality by 27% for patients with a LVEF
≤35%, if they are 40 days from myocardial infarction and ≥3
months from a coronary revascularization procedure, without a
previous cardiac arrest or symptomatic ventricular arrhythmias.
This beneﬁcial effect of ICD-only therapy on survival exists regard-
less of whether a patient has left ventricular dysfunction due to
CAD or DCM.
Study limitations
Our analysis has several limitations. First, we could not obtain indi-
vidual patient data, which offers the possibility to explore sub-
groups which may beneﬁt more or less from ICD therapy. The
conclusions of this analysis are limited by the available data.
Another possible limitation of our analysis is the inﬂuence of pub-
lication bias. This type of bias was minimized by an extensive search
and through the inclusion of unpublished data in our analysis. We
performed funnel-plot analysis which did not indicate publication
bias, although the power is limited due to the small number of
included studies.
Conclusion
The results of our meta-analysis provide strong evidence support-
ing the beneﬁcial effect of ICD-only therapy on survival of patients
with LVEF ≤35% due to ischaemic or non-ischaemic heart disease,
if they are 40 days from myocardial infarction and at least 3 months
from a coronary revascularization procedure.
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Figure 3 Arrhythmic mortality among primary prevention trials. For each randomized trial, the number of deaths (n) and the number
assigned (N) are shown. The point estimates of the relative risk (RR) for individual studies are represented by squares with 95% conﬁdence
intervals (CIs) shown as bars. The midpoint of the diamond represents the overall pooled estimate of the RR, and the 95% CI is represented
by the horizontal tips of the diamond. Abbreviations are the same as in Figure 1.
Figure 4 Rates of appropriate implantable cardioverter-
deﬁbrillator therapy. Abbreviations are the same as in Figure 1.
Meta-analysis of prophylactic ICD therapy 1569Funding
This study was supported by ‘College voor zorgverzekeringen’ ﬁled
under project number OP08/642/07. Funding to pay the Open
Access publication charges was provided by Thoraxcentrum Research
BV in Rotterdam.
References
1. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G et al.
Sudden death in patients with myocardial infarction and left ventricular dysfunc-
tion, heart failure, or both. N Engl J Med 2005;352:2581–8.
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhyth-
mias. N Engl J Med 2001;345:1473–82.
3. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved
survival with an implanted deﬁbrillator in patients with coronary disease at high
risk for ventricular arrhythmia. Multicenter Automatic Deﬁbrillator Implantation
Trial Investigators. N Engl J Med 1996;335:1933–40.
4. The Antiarrhythmics versus Implantable Deﬁbrillators (AVID) Investigators. A
comparison of antiarrhythmic-drug therapy with implantable deﬁbrillators in
patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;
337:1576–83.
5. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic
implantation of a deﬁbrillator in patients with myocardial infarction and reduced
ejection fraction. N Engl J Med 2002;346:877–83.
6. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or
an implantable cardioverter-deﬁbrillator for congestive heart failure. N Engl J Med
2005;352:225–37.
7. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/
AHA/ESC 2006 guidelines for management of patients with ventricular arrhyth-
mias and the prevention of sudden cardiac death: a report of the American
College of Cardiology/American Heart Association Task Force and the European
Society of Cardiology Committee for Practice Guidelines (Writing Committee to
Develop guidelines for management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death) developed in collaboration with the
European Heart Rhythm Association and the Heart Rhythm Society. Europace
2006;8:746–837.
8. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS
et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac
Rhythm Abnormalities: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Writing Committee to
Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of
Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration
with the American Association for Thoracic Surgery and Society of Thoracic
Surgeons. J Am Coll Cardiol 2008;51:e1–62.
9. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al.
The effect of cardiac resynchronization on morbidity and mortality in heart
failure. N Engl J Med 2005;352:1539–49.
10. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M,
Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality
and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J
2006;27:2682–88.
11. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable
cardioverter-deﬁbrillator therapy for the prevention of sudden cardiac death.
J Am Coll Cardiol 2008;52:1111–21.
12. Lee DS, Tu JV, Austin PC, Dorian P, Yee R, Chong A et al. Effect of cardiac and
noncardiac conditions on survival after deﬁbrillator implantation. J Am Coll Cardiol
2007;49:2408–15.
13. Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable
cardioverter-deﬁbrillator lead failure. Heart Rhythm 2009;6:605–10.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials 1996;17:1–12.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:
177–88.
16. Bigger JT Jr. Prophylactic use of implanted cardiac deﬁbrillators in patients at high
risk for ventricular arrhythmias after coronary-artery bypass graft surgery.
Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med
1997;337:1569–75.
17. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K et al. Primary
prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Car-
diomyopathy Trial (CAT). Circulation 2002;105:1453–58.
18. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL et al.
Amiodarone versus implantable cardioverter-deﬁbrillator: randomized trial in
patients with nonischemic dilated cardiomyopathy and asymptomatic nonsus-
tained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol 2003;41:1707–12.
19. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP et al. Prophylactic
deﬁbrillator implantation in patients with nonischemic dilated cardiomyopathy. N
Engl J Med 2004;350:2151–8.
20. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R et al. Pro-
phylactic use of an implantable cardioverter-deﬁbrillator after acute myocardial
infarction. N Engl J Med 2004;351:2481–8.
21. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Haﬂey G. A ran-
domized study of the prevention of sudden death in patients with coronary
artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J
Med 1999;341:1882–90.
22. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al.
Cardiac-resynchronization therapy with or without an implantable deﬁbrillator
in advanced chronic heart failure. N Engl J Med 2004;350:2140–50.
23. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al.
Mortality and morbidity in patients receiving encainide, ﬂecainide, or placebo. The
Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–8.
24. Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW.
Interaction of ischaemia and encainide/ﬂecainide treatment: a proposed mechan-
ism for the increased mortality in CAST I. Br Heart J 1995;74:631–5.
25. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC et al. Effectiveness
of implantable deﬁbrillators for preventing arrhythmic events and death: a
meta-analysis. J Am Coll Cardiol 2003;41:1573–82.
26. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al.
Systematic review: implantable cardioverter deﬁbrillators for adults with left ven-
tricular systolic dysfunction. Ann Intern Med 2007;147:251–62.
27. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F et al.
Impact of implantable cardioverter-deﬁbrillator, amiodarone, and placebo on
the mode of death in stable patients with heart failure. Analysis from the
Sudden Cardiac Death in Heart Failure Trial. Circulation 2009;120:2170–6.
28. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT et al. Implan-
table cardioverter deﬁbrillators and cardiac resynchronization therapy in patients
with left ventricular dysfunction: randomized trial evidence through 2004. Am
Heart J 2005;149:1020–34.
29. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable deﬁbrillators for the
prevention of mortality in patients with nonischemic cardiomyopathy: a
meta-analysis of randomized controlled trials. JAMA 2004;292:2874–9.
30. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable
cardioverter-deﬁbrillator therapy in patients with left ventricular systolic dysfunc-
tion: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:
2166–72.
31. Reuter S, Garrigue S, Barold SS, Jais P, Hocini M, Haissaguerre M et al.
Comparison of characteristics in responders versus nonresponders with biventri-
cular pacing for drug-resistant congestive heart failure. Am J Cardiol 2002;89:
346–50.
32. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al.
Cardiac-resynchronization therapy for the prevention of heart-failure events. N
Engl J Med 2009;361:1329–38.
33. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A et al.
The European cardiac resynchronization therapy survey. Eur Heart J 2009;30:
2450–60.
34. van Erven L, van Dessel PFHM, Simmers TA, Gelder IC, Hauer RNW, Wever EFD
et al. Guidelines ICD implantation—an update. http://www.nvvc.nl/media/richtlijn/25/
Guidelines.ICD.implantation.2005-an.update.pdf. 2005.
35. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D
et al. Deﬁbrillator implantation early after myocardial infarction. N Engl J Med
2009;361:1427–36.
36. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML et al. Time
dependence of mortality risk and deﬁbrillator beneﬁt after myocardial infarction.
Circulation 2004;109:1082–4.
D.A.M.J. Theuns et al. 1570